KMT2D and diffuse large B-cell lymphoma: (Targeting KDM5 demethylases counteracts KMT2D loss of function in diffuse large B-cell lymphoma; Heward et al., 2021) Additionally, reactivation of silenced CD40 pathway genes by KDM5i yields a powerful synthetic lethal effect in combination with CD40 agonist antibodies (Targeting KDM5 demethylases counteracts KMT2D loss of function in diffuse large B-cell lymphoma), which can open the opportunity for novel combination targeted therapies.